PORTLAND, Ore., Jan. 17 /PRNewswire-FirstCall/ --
Bioject Medical Technologies, Inc, (Nasdaq: BJCT), a leading developer of
needle-free drug delivery systems, today announced that it will host its
third-quarter fiscal 2002 conference call on Thursday, January 24, at
10:00 a.m. Eastern Standard Time. To participate in the call via telephone,
please dial 800-388-8975, or to hear the call live over the Internet, visit
http://www.bioject.com. A conference call replay will be available until
January 31, 2002. To listen to the replay, please dial 800-428-6051, replay
pass code 226463.
Bioject Medical Technologies Inc., based in Portland, Oregon, is an
innovative developer and manufacturer of needle-free drug delivery systems.
Needle-free injection works by forcing medication at high speed through a tiny
orifice held against the skin. This creates a fine stream of high-pressure
fluid penetrating the skin and depositing medication in the tissue beneath.
The company is focused on developing mutually beneficial agreements with
leading pharmaceutical and biotechnology companies. Bioject's partners
include Amgen, Serono and Alkermes.
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors
which may cause the actual results, performance or achievements of the
company, or industry results, to be materially different from any future
results, performance, or achievements expressed or implied by such forward
looking statements. Readers of this press release are referred to the
company's filings with the Securities and Exchange Commission, including the
company's Annual Report on Form 10-K for the year ended March 31, 2001 for
further discussions of factors that could affect future results.
Forward-looking statements are based on the estimates and opinions of
management on the date the statements are made. The company assumes no
obligation to update forward-looking statements if conditions or management's
estimates or opinions should change.
More information can be found at Bioject's home page at:
http://www.bioject.com/ .
SOURCE Bioject Medical Technologies, Inc.
 back to top
Related links:
http://www.bioject.com
Company News On-Call:
http://www.prnewswire.com/comp/101750.html
CONTACT:
Cecelia C. Heer, Investor Relations Manager
of Bioject Medical Technologies Inc., +1-973-605-8554, or
cheer@bioject.com; or IR/Media, Jim Flanagan of IR Strategic
Advisors, +1-781-863-1333, or jflanagan@iradvisors.com, for
Bioject Medical Technologies, Inc.
|
